Spineway SA (37S) Stock Price & Analysis
37S Stock Chart & Stats
- Day’s Range
- EUR 0.08 - EUR 0.09
- 52-Week Range
- EUR 0.08 - EUR 0.21
- Previous Close
- EUR 0.09
- Volume
- 0
- Average Volume (3M)
- 502
- Market Cap
- EUR 3.09M
- Enterprise Value
- EUR 3.44M
- Total Cash (Recent Filing)
- EUR 3.50M
- Total Debt (Recent Filing)
- EUR 1.53M
- Price to Earnings (P/E)
- ―
- Beta
- 0.55
- Next Earnings
- N/A
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Revenue And Margin Recovery
Steady multi-year revenue growth and recovering gross margin indicate improving commercial traction and operating economics. If this trend continues, Spineway should have a stronger base for scaling its spinal implant portfolio, supporting better earnings quality over the next several quarters.
Improving Operating Cash Flow
The return to positive operating cash flow is a constructive sign that the core business is converting activity into cash more effectively. Sustaining this improvement would reduce reliance on external funding and provide greater flexibility to support operations and product development.
Conservative Leverage
Very low leverage gives Spineway balance-sheet resilience while it works toward profitability. Limited debt reduces financing pressure and preserves capacity to absorb operating volatility, fund commercial priorities, or invest in the business without the constraints associated with heavier borrowing.
Bears Say
Persistent Net Losses
Persistent net losses show that revenue growth and gross-margin recovery have not yet translated into sustainable bottom-line profitability. Until operating costs are covered by gross profit, Spineway’s earnings quality remains weak and the business may struggle to compound value internally.
Limited Free Cash Flow
Operating cash flow improvement has not yet produced meaningful positive free cash flow after investment needs. This limits internally generated funding for expansion and leaves less flexibility to manage ongoing losses, making durable cash generation an important unresolved business requirement.
Negative Return On Equity
Negative return on equity indicates that the company is not yet generating profits from the capital invested in the business. Continued underutilization of the equity base can constrain long-term capital efficiency and reinforces the need for operating improvements to reach sustainable profitability.
Spineway SA News
37S FAQ
What was Spineway SA’s price range in the past 12 months?
What is Spineway SA’s market cap?
When is Spineway SA’s upcoming earnings report date?
How were Spineway SA’s earnings last quarter?
Is Spineway SA overvalued?
Does Spineway SA pay dividends?
What is Spineway SA’s EPS estimate?
How many shares outstanding does Spineway SA have?
What happened to Spineway SA’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Spineway SA?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Spineway SA
Spineway SA designs, develops, and markets a range of surgical implants for spine in France. The company offers posterior fixation, including posterior osteosynthesis systems and minimal invasive posterior osteosynthesis systems; interbody fusion products, such as lumbar cage twin peaks tlif curved and oblique; motion preservation products; and biomaterials. It also exports its products. The company was incorporated in 2005 and is headquartered in Ecully, France.
- Sector
- Healthcare
- Industry
- Medical - Specialties
- CEO
- Stéphane Le Roux
- Employees
- 43
- Website
- www.spineway.com
- Address
- 7, allEe Moulin Berger, Ecully, AR, 69130, FR
Spineway SA (37S) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 4 | 4 | 14 |
| Technical Analysis | 4 | 4 | 2 |
| Moving Averages | 0 | 0 | 12 |